Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRKCQ | Q04759 | 2/20 | 0.57 |
| ▸ | ULK1 | O75385 | 1/20 | 0.49 |
| ▸ | ULK2 | Q8IYT8 | 1/20 | 0.49 |
| ▸ | BCL6 | P41182 | 3/20 | 0.47 |
| ▸ | ALK | Q9UM73 | 8/20 | 0.45 |
| ▸ | EGFR | P00533 | 3/20 | 0.43 |
| ▸ | ITK | Q08881 | 2/20 | 0.43 |
| ▸ | AURKA | O14965 | 1/20 | 0.41 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.41 |
| ▸ | BRD4 | O60885 | 2/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3496207 | 0.95 | PRKCQ (0.55) | PRKCQULK1ULK2BCL6ALK | |
| SCHEMBL3494008 | 0.93 | PRKCQ (0.57) | PRKCQULK1ULK2BCL6ALK | |
| SCHEMBL3494648 | 0.93 | PRKCQ (0.61) | PRKCQULK1ULK2BCL6ALK | |
| SCHEMBL1742536 | 0.91 | PRKCQ (0.51) | PRKCQULK1ULK2BCL6ALK | |
| SCHEMBL3496408 | 0.90 | BRD4 (0.51) | PRKCQULK1ULK2BCL6ALK | |
| SCHEMBL1740953 | 0.89 | PRKCQ (0.51) | PRKCQULK1ULK2BCL6ALK | |
| SCHEMBL3495061 | 0.89 | PRKCQ (0.61) | PRKCQULK1ULK2BCL6ALK | |
| SCHEMBL3496821 | 0.89 | ULK1 (0.66) | PRKCQULK1ULK2BRD4 | |
| SCHEMBL3495546 | 0.89 | ULK1 (0.50) | PRKCQULK1ULK2BCL6ALK | |
| SCHEMBL3496203 | 0.89 | PRKCQ (0.57) | PRKCQULK1ULK2BCL6ALK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2183225-A1 | CYCLIC AMINE SUBSTITUTED PYRIMIDINEDIAMINES AS PKC INHIBITORS | Rigel Pharmaceuticals, Inc. (US) | 2010-05-12 | — | — | EP | claimed |
| CN-101405277-A | Dicarbonylic compounds with antibacterial activity | SALVAT LAB SA (ES) | 2009-04-08 | — | — | CN | claimed |
| WO-2009012421-A1 | CYCLIC AMINE SUBSTITUTED PYRIMIDINEDIAMINES AS PKC INHIBITORS | RIGEL PHARMACEUTICALS, INC. (US) | 2009-01-22 | — | — | WO | claimed |
| US-10544133-B2 | Heteroaryl substituted pyridyl compounds useful as kinase modulators | BRISTOL-MYERS SQUIBB COMPANY (US) | 2020-01-28 | — | — | US | disclosed |
| US-20180370956-A1 | HETEROARYL SUBSTITUTED PYRIDYL COMPOUNDS USEFUL AS KINASE MODULATORS | BRISTOL MYERS SQUIBB CO (US) | 2018-12-27 | — | — | US | disclosed |
| US-10023562-B2 | Heteroaryl substituted pyridyl compounds useful as kinase modulators | BRISTOL-MYERS SQUIBB COMPANY (US) | 2018-07-17 | — | — | US | disclosed |
| US-20170210730-A1 | HETEROARYL SUBSTITUTED PYRIDYL COMPOUNDS USEFUL AS KINASE MODULATORS | BRISTOL MYERS SQUIBB CO (US) | 2017-07-27 | — | — | US | disclosed |
| US-9657009-B2 | Heteroaryl substituted pyridyl compounds useful as kinase modulators | BRISTOL-MYERS SQUIBB COMPANY (US) | 2017-05-23 | — | — | US | disclosed |
| EP-2917206-B1 | HETEROARYL SUBSTITUTED PYRIDYL COMPOUNDS USEFUL AS KINASE MODULATORS | BRISTOL MYERS SQUIBB CO (US) | 2016-12-21 | — | — | EP | disclosed |
| US-20150284382-A1 | HETEROARYL SUBSTITUTED PYRIDYL COMPOUNDS USEFUL AS KINASE MODULATORS | BRISTOL-MYERS SQUIBB COMPANY | 2015-10-08 | — | — | US | disclosed |
| EP-2917206-A1 | HETEROARYL SUBSTITUTED PYRIDYL COMPOUNDS USEFUL AS KINASE MODULATORS | Bristol-Myers Squibb Company (US) | 2015-09-16 | — | — | EP | disclosed |
| US-20100179140-A1 | INDENOISOQUINOLINONE ANALOGS AND METHODS OF USE THEREOF | INOTEK PHARMACEUTICALS CORPORATION (US) | 2010-07-15 | — | — | US | disclosed |
| US-20100179165-A1 | METHODS FOR TREATING INFLAMMATORY DISORDERS USING 2,4-PYRIMIDINEDIAMINE COMPOUNDS | MIDCAP FINANCIAL TRUST | 2010-07-15 | — | — | US | disclosed |
| EP-2183225-A1 | CYCLIC AMINE SUBSTITUTED PYRIMIDINEDIAMINES AS PKC INHIBITORS | Rigel Pharmaceuticals, Inc. (US) | 2010-05-12 | — | — | EP | disclosed |
| CN-100572379-C | Cgrp receptor antagonists | MERCK & CO INC (US) | 2009-12-23 | — | — | CN | disclosed |
| CN-101405277-A | Dicarbonylic compounds with antibacterial activity | SALVAT LAB SA (ES) | 2009-04-08 | — | — | CN | disclosed |
| WO-2009012421-A1 | CYCLIC AMINE SUBSTITUTED PYRIMIDINEDIAMINES AS PKC INHIBITORS | RIGEL PHARMACEUTICALS, INC. (US) | 2009-01-22 | — | — | WO | disclosed |
| CN-101035764-A | 4-trifluoromethoxy phenoxy benzene-4' -sulfonic acid, preparation method and application thereof in medicine | SANOFI AVENTIS DEUTSCHLAND (DE) | 2007-09-12 | — | — | CN | disclosed |
| CN-1802369-A | CGRP receptor antagonists | MERCK & CO INC (US) | 2006-07-12 | — | — | CN | disclosed |
| US-6248918-B1 | BIS(DIHYDROCARBYLPHOSPHINOYLALKYL)-1,1'-BINAPHTHOL) AND RARE EARTH OR GROUP 3A METAL SALTS | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2001-06-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10544133-B2 | Heteroaryl substituted pyridyl compounds useful as kinase modulators | IRAK4, IRAK3, IRAK2 | PRKCQ 861/4885ULK1 570/4885ULK2 483/4885 |
| US-20150284382-A1 | HETEROARYL SUBSTITUTED PYRIDYL COMPOUNDS USEFUL AS KINASE MODULATORS | IRAK4, IRAK3, IRAK2 | PRKCQ 974/4885ULK1 669/4885ULK2 554/4885 |
| US-10023562-B2 | Heteroaryl substituted pyridyl compounds useful as kinase modulators | IRAK4, IRAK3, IRAK2 | PRKCQ 861/4885ULK1 570/4885ULK2 483/4885 |
| US-20100179165-A1 | METHODS FOR TREATING INFLAMMATORY DISORDERS USING 2,4-PYRIMIDINEDIAMINE COMPOUNDS | IL2, IL17A, IL23R | PRKCQ 3232/4885ULK1 1807/4885ULK2 891/4885 |
| US-20100179140-A1 | INDENOISOQUINOLINONE ANALOGS AND METHODS OF USE THEREOF | TNNI3, IDH2, GLS | PRKCQ 2586/4885ULK1 2303/4885ULK2 2252/4885 |
| US-20180370956-A1 | HETEROARYL SUBSTITUTED PYRIDYL COMPOUNDS USEFUL AS KINASE MODULATORS | IRAK4, IRAK3, IRAK2 | PRKCQ 861/4885ULK1 570/4885ULK2 483/4885 |
| US-20170210730-A1 | HETEROARYL SUBSTITUTED PYRIDYL COMPOUNDS USEFUL AS KINASE MODULATORS | IRAK4, IRAK3, IRAK2 | PRKCQ 861/4885ULK1 570/4885ULK2 483/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.